We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 689

Irreparable harm no longer presumed in the Third Circuit for Lanham Act plaintiffs

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 23 2014

In a recent decision, the Court of Appeals for the Third Circuit eliminated the presumption of irreparable harm for Lanham Act plaintiffs seeking

Update on Mayo Myriad patent eligibility from USPTO BCP Partnership Meeting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 18 2014

On September 17, 2015, the USPTO held the first "bicoastal" BiotechnologyChemicalPharmaceutical Customer Partnership meeting, with live

Court finds patent indefiniteness in unobtrusive claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 15 2014

In Interval Licensing LLC v. AOL, Inc., the Federal Circuit applied the test for patent indefiniteness set forth in the recent Supreme Court decision

Federal Circuit frames test for patent-eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 8 2014

Personalized medicine relies on diagnostics to analyze a patient for individualized therapy and for monitoring a patient's health status. Some

Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Federal Circuit upholds validity of Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 28 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Humira patent invalid for obviousness type double patenting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering

Will the USPTO respond to public feedback of its eligibility guidance?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

Periodically, the USPTO holds open meetings with the public to discuss its thinking on current topics relating to the patent procurement process

Are permanent injunctions in patent cases back in style?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 21 2014

Two recent district court decisions out of the District of Delaware have again placed the spotlight on permanent injunctions in patent cases. Prior

Airing the USPTO’s naturally occurring dirty laundry -- the subject matter eligibility stain

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 21 2014

It has been five months since the USPTO issued its Guidance For Determining Subject Matter Eligibility of Claims Reciting Or Involving Laws of Nature